Clinical Trials Directory

Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy

This study will investigate the effects of rosiglitazone, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. The primary purpose of the study is to determine whether treatment with an insulin-sensitizing medication will improve the heart's ability to metabolize glucose (sugar).

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : Rosiglitazone therapy

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Diagnosis of nonischemic dilated cardiomyopathy, current NYHA class I-II congestive heart failure - History of Stage C-D heart failure with EF ? 40% during the course of the disease - Treatment with a stable comprehensive heart failure regimen for at least 3 months (including beta-blockers and ACE-inhibitors or angiotensin receptor blockers unless intolerant) - Age > 18 yrs

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Michael B Fowler, MB
650-723-7846
Not Recruiting

Footer Links: